Theranos company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

theranos.com

Founded Year

2004

Stage

Dead | Dead

Total Raised

$500M

About Theranos

Theranos is a biomedical device company working on the field of Theranostics, the integration of technology with medical therapies to deliver the RIGHT drug, in the RIGHT dose, to the RIGHT patient at the RIGHT time. Theranos aims to provide clinical decision-support systems that enable pharmaceutical companies to develop safer, more efficacious drugs for individualized patient treatment.

Theranos Headquarter Location

1701 Page Mill Road

Palo Alto, California, 94304,

United States

650-838-9292

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Theranos

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Theranos in 2 CB Insights research briefs, most recently on Apr 19, 2022.

Expert Collections containing Theranos

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Theranos is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

11,364 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

701 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

H

Health IT

7,900 items

Theranos Patents

Theranos has filed 303 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Blood tests
  • Analytical chemistry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/5/2019

5/3/2022

Wireless networking, Computer network security, Network protocols, Mobile virtual network operators, Computer networking

Grant

Application Date

9/5/2019

Grant Date

5/3/2022

Title

Related Topics

Wireless networking, Computer network security, Network protocols, Mobile virtual network operators, Computer networking

Status

Grant

Latest Theranos News

Luckin, the Theranos of Chinese coffee, plots an improbable comeback from delisting and bankruptcy - Fortune

May 23, 2022

Not a member yet? Free Membership for Qualified Investors and Industry Participants Easily Customize Content to Match Your Investment Preferences Breaking News 24/7/365 Alternative Investment Listings & LeaderBoards Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets,Presentations, Investment Mandates, Video PitchBooks & More! Company Directory AUM Accelerator Program (designed for investment managers) Over 450K+ Industry Headlines, Posts and Updates ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY.CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN.PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.THIS IS NOT A SOLICITATION FOR INVESTMENT.THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY.IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES.ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM.PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT. ALPHAMAVEN

  • When was Theranos founded?

    Theranos was founded in 2004.

  • Where is Theranos's headquarters?

    Theranos's headquarters is located at 1701 Page Mill Road, Palo Alto.

  • What is Theranos's latest funding round?

    Theranos's latest funding round is Dead.

  • How much did Theranos raise?

    Theranos raised a total of $500M.

  • Who are the investors of Theranos?

    Investors of Theranos include Fortress Investment Group, Rupert Murdoch, Cox Enterprises, Riley Bechtel, Threshold Ventures and 17 more.

  • Who are Theranos's competitors?

    Competitors of Theranos include Banyan Biomarkers and 4 more.

You May Also Like

S
SunTen Phytotech

SunTen Phytotech (STPT) develops botanical medicines and functional dietary products with proven efficacy and safety, constructs advanced technical platforms for new botanical drug research and development, and aims to provide CMC services of botanical products. SunTen also aims to provide high quality services in developing bio-medical products.

D
Delphic Diagnostics

Delphic aims to provide a full suite of HIV diagnostics, from simple viral load testing through to advanced genetic tests, to pharmaceutical organisations and clinicians. Some of Delphic's tests are and have been developed internally. As part of MMC's investment, the University of Liverpool's Therapeutic Drug Monitoring service, was "˜spun in' to the business.

S
Stat Analysis

Stat Analysis is a full-service analytical support laboratory (rapid analytical turnaround times, 24/7 operations, and the ability to analyze large numbers of samples) that aims to serve pharmaceutical, environmental, product safety, industrial hygiene, and health care industries.

O
OcuNexus Therapeutics

OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.

V
Vasopharm

Vasopharm develops therapeutics for acute inflammatory central nervous system conditions by targeting nitric oxide signaling pathways. The company focuses on drug development in central nervous system (CNS) niche indications with a high unmet medical need. It has taken a small molecule (VAS203) targeting pathological nitric oxide (NO) production and signaling from discovery to a pivotal clinical trial.

CSEM Logo
CSEM

CSEM, the Swiss Center for Electronics and Microtechnology, is a research and development company active in applied research, product development, prototype and low-volume production, and technology consulting. Its main fields of activity are micro- and nanotechnologies, microelectronics, systems engineering, microrobotics, photonics, information and communication technologies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.